Celgene Absolute Bioavailability Data – ASCPT 2010 Poster
CC-11050 is a novel anti-inflammatory with specific phosphodiesterase type IV (PDE4) inhibition activity.: Absolute Bioavailability of CC-11050, a low water soluble NCE, using an IV microdose of [14C]-CC-11050 solution concomitantly with an oral unlabelled dose. The analysis of the trace amount of [14C] labelled parent drug is achieved by AMS.
Poster presented at ASCPT 2010 by Celgene and Quotient Clinical.
CC-11050 is a novel anti-inflammatory with specific phosphodiesterase type IV (PDE4) inhibition activity. presentation
GSK publish on the use of AMS to determine the absolute bioavailability of dabrafenib, a BRAF inhibitor, in patients
"...AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."
Find out how we can help you accelerate your drug-development program.